Quince Therapeutics (QNCX) Q4 2025 earnings summary

Executive summary

• Lead drug candidate eDSP failed to meet primary and secondary endpoints in the pivotal Phase 3 NEAT trial for A-T, halting further development and leaving no other product candidates in the pipeline.

• The company is now focused on preserving cash and evaluating strategic alternatives, including a potential reverse merger, with no current agreements in place.

• LifeSci Capital was engaged as exclusive financial advisor in February 2026 to assist with restructuring and strategic review.

Financial highlights

• Net loss for 2025 was $84.0 million, up from $56.8 million in 2024, driven by increased R&D expenses and fair value adjustments.

• Research and development expenses rose 90% year-over-year to $35.4 million, mainly due to Phase 3 NEAT trial costs.

• General and administrative expenses decreased 14% to $15.0 million.

• Cash, cash equivalents, and short-term investments totaled $17.8 million as of December 31, 2025.

• Accumulated deficit reached $460.5 million at year-end 2025.

• Additional $20.4 million raised post-year-end via ATM program.

Outlook and guidance

• Substantial doubt exists regarding ability to continue as a going concern for the next 12 months without additional funding.

• Operations expected to be funded into Q2 2026, or into the second half if warrants are exercised in full for cash.

• No expectation of revenue generation unless a strategic transaction is completed.